SOS2 regulates the threshold of mutant EGFR-dependent oncogenesis

Son of Sevenless 1 and 2 (SOS1 and SOS2) are RAS guanine nucleotide exchange factors (RasGEFs) that mediate physiologic and pathologic RTK-dependent RAS activation. Here, we show that SOS2 modulates the threshold of epidermal growth factor receptor (EGFR) signaling to regulate the efficacy of and resistance to the EGFR-TKI osimertinib in lung adenocarcinoma (LUAD). SOS2 deletion sensitized EGFR-mutated cells to perturbations in EGFR signaling caused by reduced serum and/or osimertinib treatment to inhibit PI3K/AKT pathway activation, oncogenic transformation, and survival. Bypass RTK reactivation of PI3K/AKT signaling represents a common resistance mechanism to EGFR-TKIs; SOS2 KO reduced PI3K/AKT reactivation to limit osimertinib resistance. In a forced HGF/MET-driven bypass model, SOS2 KO inhibited HGF-stimulated PI3K signaling to block HGF-driven osimertinib resistance. Using a long term in situ resistance assay, a majority of osimertinib resistant cultures exhibited a hybrid epithelial/mesenchymal phenotype associated with reactivated RTK/AKT signaling. In contrast, RTK/AKT-dependent osimertinib resistance was markedly reduced by SOS2 deletion; the few SOS2 KO cultures that became osimertinib resistant primarily underwent non-RTK dependent EMT. Since bypass RTK reactivation and/or tertiary EGFR mutations represent the majority of osimertinib-resistant cancers, these data suggest that targeting SOS2 has the potential to eliminate the majority of osimertinib resistance. One sentence summary SOS2 modulates the threshold of EGFR-PI3K signaling to regulate the efficacy of and resistance to osimertinib.

[1]  J. W. Askew,et al.  SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status , 2023, bioRxiv.

[2]  R. Kortum,et al.  In situ modeling of acquired resistance to RTK/RAS pathway targeted therapies , 2023, bioRxiv.

[3]  I. Waizenegger,et al.  Combined KRASG12C and SOS1 inhibition enhances and extends the anti-tumor response in KRASG12C-driven cancers by addressing intrinsic and acquired resistance , 2023, bioRxiv.

[4]  Fang Wu,et al.  The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer , 2021, Frontiers in Oncology.

[5]  Xiaozhuo Chen,et al.  Cancer stem cells, epithelial-mesenchymal transition, ATP and their roles in drug resistance in cancer , 2021, Cancer drug resistance.

[6]  R. Kortum,et al.  Breaking Oncogene Addiction: Getting RTK/RAS-Mutated Cancers off the SOS. , 2021, Journal of medicinal chemistry.

[7]  Lin-lin Sun,et al.  Targeting the EMT transcription factor Snail overcomes resistance to osimertinib in EGFR‐mutant non‐small cell lung cancer , 2021, Thoracic cancer.

[8]  R. Kortum,et al.  The Role of Wild-Type RAS in Oncogenic RAS Transformation , 2021, Genes.

[9]  P. Ettmayer,et al.  One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRAS. , 2021, Journal of medicinal chemistry.

[10]  R. Kortum,et al.  Marked synergy by vertical inhibition of EGFR signaling in NSCLC spheroids shows SOS1 is a therapeutic target in EGFR-mutated cancer , 2020, eLife.

[11]  P. Ettmayer,et al.  BI-3406, a potent and selective SOS1::KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition. , 2020, Cancer discovery.

[12]  M. McMahon,et al.  Inhibition of MEK1/2 Forestalls the Onset of Acquired Resistance to Entrectinib in Multiple Models of NTRK1-Driven Cancer. , 2020, Cell reports.

[13]  G. Tortora,et al.  Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives , 2020, Cancers.

[14]  Anna L. Brown,et al.  Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer , 2020, Cell reports medicine.

[15]  Raymond B. Runyan,et al.  Guidelines and definitions for research on epithelial–mesenchymal transition , 2020, Nature Reviews Molecular Cell Biology.

[16]  D. Pe’er,et al.  Lineage plasticity in cancer: a shared pathway of therapeutic resistance , 2020, Nature Reviews Clinical Oncology.

[17]  Henry W. Long,et al.  Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway. , 2020, Cancer cell.

[18]  Davide Risso,et al.  Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition , 2020, Nature.

[19]  Hiromasa Yamamoto,et al.  YES1 activation induces acquired resistance to neratinib in HER2‐amplified breast and lung cancers , 2019, Cancer Science.

[20]  F. Fece de la Cruz,et al.  Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition , 2019, Clinical Cancer Research.

[21]  Ying Cheng,et al.  Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. , 2019, The New England journal of medicine.

[22]  R. Doebele Acquired Resistance Is Oncogene and Drug Agnostic. , 2019, Cancer cell.

[23]  E. Giovannetti,et al.  Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer , 2019, British Journal of Cancer.

[24]  N. Haginoya,et al.  DS-1205b, a novel selective inhibitor of AXL kinase, blocks resistance to EGFR-tyrosine kinase inhibitors in a non-small cell lung cancer xenograft model , 2019, Oncotarget.

[25]  P. Hammerman,et al.  Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers , 2019, Molecular Cancer Therapeutics.

[26]  J. Ahn,et al.  Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer , 2019, Investigational New Drugs.

[27]  R. Kortum,et al.  Anchorage-independent growth conditions reveal a differential SOS2 dependence for transformation and survival in RAS-mutant cancer cells , 2019, Small GTPases.

[28]  Donghwa Kim,et al.  AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells , 2019, Cell Death & Disease.

[29]  H. Briem,et al.  Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interaction , 2019, Proceedings of the National Academy of Sciences.

[30]  S. Yano,et al.  AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells , 2019, Nature Communications.

[31]  R. Sachidanandam,et al.  SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors , 2019, Cell reports.

[32]  J. Soh,et al.  Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR-Mutant Non–Small Cell Lung Cancer Cells , 2018, Molecular Cancer Research.

[33]  L. Crinò,et al.  Epithelial‐to‐mesenchymal transition in the context of epidermal growth factor receptor inhibition in non‐small‐cell lung cancer , 2018, Biological reviews of the Cambridge Philosophical Society.

[34]  Dong-Wan Kim,et al.  Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib , 2018, Cancer research and treatment : official journal of Korean Cancer Association.

[35]  D. Morrison,et al.  Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation , 2018, Science Signaling.

[36]  C. Rudin,et al.  Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer , 2018, Oncogene.

[37]  B. Neel,et al.  SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models. , 2018, Cancer discovery.

[38]  G. Kiss,et al.  RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers , 2018, Nature Cell Biology.

[39]  T. Salame,et al.  A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways , 2018, Clinical Cancer Research.

[40]  R. Bernards,et al.  SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo , 2018, Nature Medicine.

[41]  J. Soh,et al.  Therapeutic strategies for afatinib‐resistant lung cancer harboring HER2 alterations , 2018, Cancer science.

[42]  Ying Cheng,et al.  Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[43]  T. Salame,et al.  An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors , 2017, EMBO molecular medicine.

[44]  M. Tiseo,et al.  Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines , 2017, Journal of experimental & clinical cancer research : CR.

[45]  T. Bivona,et al.  Understanding and targeting resistance mechanisms in NSCLC , 2017, Nature Reviews Cancer.

[46]  H. Ditzel,et al.  Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer , 2017, Nature Communications.

[47]  Lorin Crawford,et al.  A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution. , 2017, Cell reports.

[48]  A. Jimeno,et al.  EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases. , 2017, Cancer research.

[49]  M. Varella‐Garcia,et al.  Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling , 2017, Molecular Cancer Therapeutics.

[50]  R. Weinberg,et al.  EMT, CSCs, and drug resistance: the mechanistic link and clinical implications , 2017, Nature Reviews Clinical Oncology.

[51]  R. Salgia,et al.  Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. , 2016, Cancer letters.

[52]  C. Rudin,et al.  A combinatorial strategy for treating KRAS mutant lung cancer , 2016, Nature.

[53]  Chandra Sekhar Pedamallu,et al.  Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas , 2016, Nature Genetics.

[54]  A. Nielsen,et al.  The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. , 2016, Translational lung cancer research.

[55]  Jae Cheol Lee,et al.  Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer , 2016, Oncotarget.

[56]  M. Nowak,et al.  Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers , 2015, Nature Communications.

[57]  S. Asthana,et al.  RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK–positive lung cancer , 2015, Nature Medicine.

[58]  W. Pao,et al.  Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models. , 2015, Cancer research.

[59]  P. Jänne,et al.  Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer. , 2015, Cancer discovery.

[60]  K. Janes An analysis of critical factors for quantitative immunoblotting , 2015, Science Signaling.

[61]  Parantu K. Shah,et al.  Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer. , 2015, Cancer research.

[62]  Steven J. M. Jones,et al.  Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[63]  Neville E. Sanjana,et al.  Improved vectors and genome-wide libraries for CRISPR screening , 2014, Nature Methods.

[64]  P. Bunn,et al.  Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer , 2013, PloS one.

[65]  Carlotta Costa,et al.  MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. , 2012, Cancer research.

[66]  D. Bar-Sagi,et al.  Sos-mediated cross activation of wild-type Ras by oncogenic Ras is essential for tumorigenesis , 2012, Nature Communications.

[67]  Luca Toschi,et al.  Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. , 2010, Cancer cell.

[68]  William Pao,et al.  Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer , 2009, Proceedings of the National Academy of Sciences.

[69]  William C Hahn,et al.  Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants , 2005, PLoS medicine.

[70]  E. Dmitrovsky,et al.  Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. , 1993, Cancer research.

[71]  I. Pastan,et al.  Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene. , 1987, Science.

[72]  J. Fernandez-Banet,et al.  The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients. , 2019, Cancer discovery.

[73]  Liquid Biopsies Non-small-cell lung cancer , 2015, Nature Reviews Disease Primers.